Merck KGaA logo

Merck KGaA (MRCK)

Market Closed
11 Apr, 15:30
XWBO XWBO
115. 25
+2.65
+2.35%
- Market Cap
23.04 P/E Ratio
2.39% Div Yield
0 Volume
0 Eps
112.6
Previous Close
Day Range
112.7 115.25
Year Range
111 178.1

Summary

MRCK closed yesterday higher at €115.25, an increase of 2.35% from Thursday's close, completing a monthly decrease of -9.89% or €12.65. Over the past 12 months, MRCK stock lost -17.35%.
MRCK is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XWBO (EUR).
Want to track MRCK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

MRCK Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Merck KGaA (MRCK) FAQ

What is the stock price today?

The current price is €115.25.

On which exchange is it traded?

Merck KGaA is listed on XWBO.

What is its stock symbol?

The ticker symbol is MRCK.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Merck KGaA ever had a stock split?

No, there has never been a stock split.

Merck KGaA Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Ms. Belen Garijo Lopez M.D. CEO
XWBO Exchange
- ISIN
US Country
62,908 Employees
23 Aug 1970 Last Dividend
- Last Split
- IPO Date

Overview

Merck KGaA is a prominent science and technology entity based in Germany, spanning its operations through diversified sectors such as Life Science, Healthcare, and Electronics. As of its inception in 1668, the company has distinguished itself by contributing significantly to academic, biotech, pharmaceutical, and industrial fields with its comprehensive range of tools, chemicals, and technology solutions. It is an influential subsidiary of E. Merck KGaA, with its headquarters located in Darmstadt, Germany. Through its international collaborations and in-licensing agreements with companies like Debiopharm International SA, Jiangsu Hengrui Pharmaceuticals Co. Ltd., and Abbisko Therapeutics Co. Ltd., Merck KGaA continues to bolster its position in developing innovative treatments in areas such as oncology, neurology, and various other critical disease sectors.

Products and Services

  • Life Science Solutions

    Merck KGaA offers an extensive suite of products tailored for the Life Science industry, catering to academic labs, biotech, and pharmaceutical manufacturers. This includes process development expertise, technologies for continuous bioprocessing, testing kits, chemical reagents, and services designed for air, water, and soil analysis. They also provide tools that assess the nutritional value and identify quality inconsistencies, aiming to support the entire biopharmaceutical manufacturing value chain.

  • Healthcare and Biopharmaceuticals

    The company plays a pivotal role in the healthcare sector by discovering, developing, manufacturing, and marketing a broad portfolio of prescription drugs and biopharmaceutical products. These offerings are directed toward treating conditions in oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. Moreover, it includes general medicines along with injection devices and disease monitoring software, stressing the importance of comprehensive patient care.

  • Electronics Segment

    Merck KGaA extends its expertise to the semiconductor and display industries by supplying critical materials and solutions for surface design. This encompasses delivery systems and services, as well as innovative surface solutions like cosmetics, effect pigments, and functional solutions. Their contributions are vital for the development and manufacturing processes in the electronics sector, showcasing their versatility and capacity to meet diverse industry needs.

  • In-licensing Agreements and Collaborations

    The company has established several significant in-licensing agreements and collaborations aimed at the development and commercialization of drug candidates. This includes partnerships for targeting conditions like head and neck cancer, metastatic colorectal cancer, and tenosynovial giant cell tumor. Such endeavors signify Merck KGaA's commitment to addressing global health challenges through innovation and strategic partnerships.

Contact Information

Address: Frankfurter Strasse 250, Darmstadt, Germany, 64293
Phone: 49 6151 72 0